Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.67 |
| ▸ | RARA | P10276 | 9/20 | 0.67 |
| ▸ | RARG | P13631 | 8/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.50 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16692946 | 0.90 | RARB (0.54) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL29840615 | 0.89 | RARB (0.52) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL19342981 | 0.89 | RARB (0.52) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL19342974 | 0.89 | RARB (0.52) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL19342901 | 0.89 | RARB (0.52) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL38662534 | 0.89 | RARB (0.50) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL19342929 | 0.88 | RARA (0.51) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL995909 | 0.87 | CYP3A4 (0.63) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL19342928 | 0.85 | RARB (0.47) | RARBRARARARGCYP3A4KMT2A | |
| SCHEMBL9270697 | 0.85 | CYP3A4 (0.77) | RARBRARARARGCYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453746-A1 | TAZAROTENE DERIVATIVES | Stiefel Laboratories, Inc. (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011009023-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| US-11026934-B2 | Topical retinoid compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2021-06-08 | — | — | US | disclosed |
| US-20210161875-A1 | TOPICAL RETINOID COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2021-06-03 | — | — | US | disclosed |
| US-10716781-B2 | Topical retinoid compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2020-07-21 | — | — | US | disclosed |
| US-20190224181-A1 | TOPICAL RETINOID COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2019-07-25 | — | — | US | disclosed |
| US-20180177774-A1 | TOPICAL RETINOID COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2018-06-28 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688667-B2 | Tazarotene with low dimer impurity for treating acne or psoriasis | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | disclosed |
| US-20140357669-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357672-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| EP-2453746-A1 | TAZAROTENE DERIVATIVES | Stiefel Laboratories, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115909-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2012-05-10 | — | — | US | disclosed |
| WO-2011009023-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2009116075-A2 | PROCESS FOR PREPARATION OF TAZAROTENE | INDOCO REMEDIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| US-7273937-B2 | Process for the preparation of Tazarotene | SOLMAG S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224181-A1 | TOPICAL RETINOID COMPOSITIONS | RARA, RXRA, RARB | RARB 3/4885RARA 1/4885RARG 4/4885 |
| US-20210161875-A1 | TOPICAL RETINOID COMPOSITIONS | RARA, RXRA, RARB | RARB 3/4885RARA 1/4885RARG 4/4885 |
| US-20160304503-A1 | TAZAROTENE WITH LOW DIMER IMPURITY FOR TREATING ACNE OR PSORIASIS | PPIA, CUTA, TFPI | RARB 130/4885RARA 77/4885RARG 294/4885 |
| US-11026934-B2 | Topical retinoid compositions | RARA, RXRA, RARB | RARB 3/4885RARA 1/4885RARG 4/4885 |
| US-20140357672-A1 | TAZAROTENE DERIVATIVES | RXRA, RARA, RXRB | RARB 5/4885RARA 2/4885RARG 6/4885 |
| US-10716781-B2 | Topical retinoid compositions | RARA, RXRA, RARB | RARB 3/4885RARA 1/4885RARG 4/4885 |
| US-20140357669-A1 | TAZAROTENE DERIVATIVES | RXRA, RARA, RXRB | RARB 5/4885RARA 2/4885RARG 6/4885 |
| US-20120115909-A1 | TAZAROTENE DERIVATIVES | RXRA, RARA, RXRB | RARB 5/4885RARA 2/4885RARG 6/4885 |
| US-20180177774-A1 | TOPICAL RETINOID COMPOSITIONS | RARA, RXRA, RARB | RARB 3/4885RARA 1/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.